(Q45367247)

English

Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy

scientific article published in July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

based on heuristic

Hepatitis B virus

1 reference

based on heuristic

1 reference

based on heuristic

author name string

Chao-Wei Hsu

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Chau-Ting Yeh

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

language of work or name

0 references

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

101-108

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Drug resistance in antiviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Detection of hepatitis B virus (HBV) genotype E carried--even in the presence of high titers of anti-HBs antibodies--by an Argentinean patient of African descent who had received vaccination against HBV

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

Occult hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

21 January 2018

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of lamivudine resistance by HBV

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24363

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.24363

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45367247&oldid=2075897388"